Long-Term Debt: NexImmune Corp (NEXI)

Brandmark of NexImmune Corporation (NEXI)

Developing T-cell-based tumor combat methods involves immense risks and severe pressure from global pharma behemoths. NexImmune, Inc. (NEXI) attracts talent through a flexible management approach and stock option programs. The company is currently shifting its model, closing some tests to monetize patents and preserve capital. Long-term debt stands at 0.00, which is clearly demonstrated by this chart of liability value changes.

NEXI (NexImmune Corp) Company Long-Term Debt history from 07/04/2022 to 08/04/2024

NexImmune Corp - analytical breakdowns and key metrics (NEXI)

- current quotes and average value forecast:
Stock Quotes neximmune.com|NEXI - Price Target Chart
- company stock exchange capitalization indicators:
Market Value NexImmune|NEXI - Total Company Value
- book capitalization data:
Net Assets per Single Share NexImmune|NEXI - Company Book Value|Market-to-Book Ratio neximmune.com|NEXI - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio NexImmune, Inc.|NEXI - Long-Term Debt to Equity Ratio|Current Liabilities to Capital NexImmune Corporation|NEXI - Company Total Debt|Debt to Net Assets Ratio NexImmune|NEXI - Company Long-Term Debts|Short-Term Debt Volume NexImmune|Quick Liquidity Indicator neximmune.com
- net income and valuation multiples indicators:
NEXI - Company Net Income
Fundamental company valuation:neximmune.com
Core merchandise of NexImmune

Fundamental risks for NexImmune, Inc. (NEXI) are determined through an analysis of its liability structure. Financing bioscreening automation and the implementation of robotic stations requires significant capital expenditures. The company's long-term debt aggregates all credit obligations with maturities exceeding twelve months. This metric measures the volume of external financing raised for strategic development. The dynamics of this indicator allow for an assessment of the debt load relative to the pace of technological scaling.

Who NexImmune, Inc. competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt Tango Therapeutics|Long-Term Debt iovance.com IOVA|Company Long-Term Debts IMTX|Xencor Inc (XNCR) - Long-Term Indebtedness|Compass Bio - Company Long-Term Liabilities|Replimune Inc. (REPL) - Long-Term Debt|LYEL: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Long-Term Debts|CGEN - Long-Term Debt Volume|Company Long-Term Debt IO Biotech Corp|Company Long-Term Liabilities Sutro Biopharma, Inc (STRO)|Company Long-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Long-Term Liabilities werewolftx.com HOWL|Immix Biopharma - Company Long-Term Liabilities|Company Long-Term Debts alxoncology.com ALXO|CUE - Company Long-Term Debt|PDSB (PDS Biotechnology) - Company Long-Term Indebtedness|sonnetbio.com (SONN) - Company Long-Term Debt|Long-Term Debt MAIABiotech.com (MAIA)|Company Long-Term Liabilities LIMN|LVTX - Long-Term Indebtedness|Company Long-Term Liabilities NXTC (NextCure Corp)|Amount of Long-Term Liabilities LPTX|Company Long-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Long-Term Loans and Borrowings SNSE|Theriva Biologics - Company Long-Term Debts|Long-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com